- Don't Miss the CEO of Samaritan On "News 3 At Sunrise" Sunday, August 26th - Samaritan is One of Nevada's Largest Pharmaceutical Companies - Samaritan Videos to Highlight the Substantial Benefits of Each Drug Over What is Currently On Market
LAS VEGAS, Aug. 24, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals, Inc. (AMEX:LIV), a developer of innovative drugs, announced today its CEO Dr. Janet Greeson, will be interviewed on the NBC Las Vegas affiliate KVBC Channel 3. "News 3 at Sunrise" will be aired early Sunday morning, August 26, from 6 AM to 7AM. Dr. Greeson will be showing videos to explain the "mechanism of action" and the drug's substantial benefit over what is currently on the market for Samaritan's Alzheimer's drug SP-233, its late stage HIV drug resistance drug SP-01A and Samaritan's Neuronal Stem Cell therapy for the potential use with Alzheimer's disease, Spinal Cord injury and Stroke.
Samaritan Pharmaceuticals: "Transforming Today's Science Into Tomorrow's Cures..."
Samaritan Pharmaceuticals is a life science company focused on commercializing its pipeline of innovative drugs to relieve the suffering of patients with Alzheimer's, cancer, heart disease, and infectious disease. Samaritan's business strategy is to partner drug candidates in its pipeline after Phase II (proof of concept) human studies. Samaritan has executed its first partnering agreement with Pharmaplaz, Ireland for its PII, HIV drug SP-01A. In addition, Samaritan's sales arm has acquired the marketing and sales rights to sell ten revenue-generating products in Greece and various Eastern European countries.
Website, http://www.samaritanpharma.com. Please register so we can notify you of upcoming conference calls, news and events.
The Samaritan Pharmaceuticals Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2670
Disclaimer
The company disclaims any information created by an outside party and endorses only information communicated by its press releases, filings, and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-Q filed August 13, 2007. The company undertakes no duty to update forward-looking statements.